Interested in specific Information?

Filter what you see here

Quick poll

NICE rejects daratumumab (Darzalex) for use second-line with bortezomib…

NICE rejects daratumumab (Darzalex) for use second-line with bortezomib and dexamethasone

Closes Jul 17, 2018

Relapsed/refractory patients

Quick poll

EHA 2018 | Pomalidomide/dexamethasone with or without elotuzumab: the…

Closes Jul 16, 2018

General MM

Quick poll

EHA 2018 | Preclinical study to assess dual BCL-2 and MCL-1 inhibition in…

Closes Jul 11, 2018 , Expert Opinion

Quick poll

EHA 2018| Phase I/IIa study of MOR202 used in combination treatments

EHA 2018| Phase I/IIa study of MOR202 used in combination treatments

Closes Jul 8, 2018 , Expert Opinion

Relapsed/refractory patients

Quick poll

EHA 2018 | Preclinical data for BCMAxCD3 bi-specific antibody JNJ-957

Closes Jul 6, 2018

General MM

Quick poll

EHA 2018 | Phase Ib study of isatuximab in combination with pomalidomide…

Closes Jul 4, 2018

Relapsed/refractory patients

Quick poll

EHA 2018 | The phase III OPTIMISMM study of pomalidomide, bortezomib and…

EHA 2018 | The phase III OPTIMISMM study of pomalidomide, bortezomib and dexamethasone

Closes Jun 28, 2018 , Expert Opinion

Patients eligible for transplant

Quick poll

EHA 2018 | Interim analysis of the phase III EMN02/HOVON 95 MM trial to…

Closes Jun 26, 2018

Quick poll

EHA 2018 | Final analysis of the Phase III GIMEMA Trial

Closes Jun 20, 2018

Relapsed/refractory patients

Quick poll

Jesus Berdeja | EHA 2018 | The CRB-401 phase I bb2121 CAR T-cell study

Jesus Berdeja | EHA 2018 | The CRB-401 phase I bb2121 CAR T-cell study

Closes Jun 17, 2018

Elderly patients

Quick poll

Sonja Zweegman | EHA 2018 | The issue of frailty in MM

Closes Jun 17, 2018

General MM

Quick poll

Paola Neri | EHA 2018 | The basis for immunotherapy in Multiple Myeloma

Closes Jun 16, 2018

General MM,   Patients eligible for transplant,  Patients non-eligible for transplant,   & 1 more

Quick poll

Niels Van de Donk | EHA 2018 | Immunotherapy in myeloma: why, when and how?

Niels Van de Donk | EHA 2018 | Immunotherapy in myeloma: why, when and how?

Closes Jun 15, 2018

Relapsed/refractory patients

Quick poll

ASCO 2018 | Updated results from the CRB-401 phase I study of bb2121 CAR…

Closes Jun 13, 2018

General MM,   Relapsed/refractory patients,  Patients eligible for transplant

Quick poll

ASCO 2018 | What happened with pembrolizumab in MM clinical trials?

Closes Jun 12, 2018
A global online educational platform sharing the latest research and emerging treatment information in multiple myeloma

Latest Medical Information

Latest Publications

Latest Biology

Latest Drug Updates

Patients eligible for transplant,Patients non-eligible for transplant,Relapsed/refractory patients

Galinpepimut-S granted FDA orphan drug designation

May 11, 2018
Patients eligible for transplant,Patients non-eligible for transplant

Daratumumab approved by FDA for frontline use

May 8, 2018

Recently updated Licenses

Where we are next

European School of Haematology (ESH) 4th International Conference on Multiple Myeloma

October 5–7, 2018 | Mandelieu, FR

The MM Hub will be attending the European School of Hematology (ESH) 4th International Conference on Myeloma, to be held in Mandelieu, France, from 5-7 October 2018. The meeting will be chaired by Kenneth C. Anderson, Maria Victoria Mateos, and Philippe Moreau, and will take place in the Congress Mandelieu Expo Center. The meeting attracts world-class leaders who present the latest clinical data and debate important and contentious issues in MM. 
#mmsm

Event Website

Map Data
Map data ©2018 Google
Map DataMap data ©2018 Google
Map data ©2018 Google

Connect with us

Our sister hubs

Visit our other community physician education hubs in haematology and oncology